These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 15225110)

  • 41. Improving walking ability and ankle brachial pressure indices in symptomatic peripheral vascular disease with intermittent pneumatic foot compression: a prospective controlled study with one-year follow-up.
    Delis KT; Nicolaides AN; Wolfe JH; Stansby G
    J Vasc Surg; 2000 Apr; 31(4):650-61. PubMed ID: 10753272
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Measuring treatment effects of cilostazol on clinical trial endpoints in patients with intermittent claudication.
    Smith JA
    Clin Cardiol; 2002 Mar; 25(3):91-4. PubMed ID: 11892686
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect on walking distance and atherosclerosis progression of a nitric oxide-donating agent in intermittent claudication.
    Gresele P; Migliacci R; Arosio E; Bonizzoni E; Minuz P; Violi F;
    J Vasc Surg; 2012 Dec; 56(6):1622-8, 1628.e1-5. PubMed ID: 22963812
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cilostazol.
    Sorkin EM; Markham A
    Drugs Aging; 1999 Jan; 14(1):63-71; discussion 72-3. PubMed ID: 10069409
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Treatment of intermittent claudication: cilostazol.
    Collins P; Brittenden J
    Hosp Med; 2004 Aug; 65(8):466-70. PubMed ID: 15330347
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A phase II dose-ranging study of the phosphodiesterase inhibitor K-134 in patients with peripheral artery disease and claudication.
    Brass EP; Cooper LT; Morgan RE; Hiatt WR
    J Vasc Surg; 2012 Feb; 55(2):381-389.e1. PubMed ID: 22119244
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Heparan sulfate in the treatment of intermittent claudication: results of a randomized, double-blind, placebo-controlled multicenter trial.
    Messa GL; Gelso E
    Drugs Exp Clin Res; 2002; 28(1):37-48. PubMed ID: 12073766
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cilostazol (pletal): a dual inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine uptake.
    Liu Y; Shakur Y; Yoshitake M; Kambayashi Ji J
    Cardiovasc Drug Rev; 2001; 19(4):369-86. PubMed ID: 11830753
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Improvement of walking distance by defibrotide in patients with intermittent claudication--results of a randomized, placebo-controlled study (the DICLIS study). Defibrotide Intermittent CLaudication Italian Study.
    Violi F; Marubini E; Coccheri S; Nenci GG
    Thromb Haemost; 2000 May; 83(5):672-7. PubMed ID: 10823260
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cilostazol in intermittent claudication.
    Cariski AT; Lindmayer K
    Am J Health Syst Pharm; 2002 Jan; 59(1):81-2. PubMed ID: 11813475
    [No Abstract]   [Full Text] [Related]  

  • 51. Pharmacological treatment of intermittent claudication does not have a significant effect on gait impairments during claudication pain.
    Yentes JM; Huisinga JM; Myers SA; Pipinos II; Johanning JM; Stergiou N
    J Appl Biomech; 2012 May; 28(2):184-91. PubMed ID: 22723116
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication.
    Stevens JW; Simpson E; Harnan S; Squires H; Meng Y; Thomas S; Michaels J; Stansby G
    Br J Surg; 2012 Dec; 99(12):1630-8. PubMed ID: 23034699
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Management of peripheral arterial disease in the elderly: focus on cilostazol.
    Falconer TM; Eikelboom JW; Hankey GJ; Norman PE
    Clin Interv Aging; 2008; 3(1):17-23. PubMed ID: 18488875
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cilostazol and outcome in outpatients with peripheral artery disease.
    Perez P; Esteban C; Sauquillo JC; Yeste M; Manzano L; Mujal A; Jiménez Caballero PE; Aguilar E; Sánchez Muñoz-Torrero JF; Monreal M;
    Thromb Res; 2014 Aug; 134(2):331-5. PubMed ID: 24951338
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Medical management of peripheral arterial disease.
    Creager MA
    Cardiol Rev; 2001; 9(4):238-45. PubMed ID: 11405904
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cilostazol: a new drug in the treatment intermittent claudication.
    Kumar M; Bhattacharya V
    Recent Pat Cardiovasc Drug Discov; 2007 Nov; 2(3):181-5. PubMed ID: 18221117
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The effect of withdrawal of drugs treating intermittent claudication.
    Dawson DL; DeMaioribus CA; Hagino RT; Light JT; Bradley DV; Britt KE; Charles BE
    Am J Surg; 1999 Aug; 178(2):141-6. PubMed ID: 10487267
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Cilostazol improves the quality of life and lower-limb functional capacity also in diabetic patients].
    Farkas K; Kolossváry E; Járai Z
    Orv Hetil; 2020 Sep; 161(38):1637-1645. PubMed ID: 32924968
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A randomized trial of iloprost in patients with intermittent claudication.
    Creager MA; Pande RL; Hiatt WR
    Vasc Med; 2008 Feb; 13(1):5-13. PubMed ID: 18372433
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Treatment for intermittent claudication and the effects on walking distance and quality of life.
    Kruidenier LM; Viechtbauer W; Nicolaï SP; Büller H; Prins MH; Teijink JA
    Vascular; 2012 Feb; 20(1):20-35. PubMed ID: 22271802
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.